comparemela.com
Latest Breaking News On - Achieved clinical remission - Page 1 : comparemela.com
Guselkumab Demonstrates Long-Term Benefit for Crohn Disease
During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.
Jan-wehkamp
Anita-afzali
Uc-health-anita-afzali
Johnson
University-of-cincinnati-college-medicine
Johnson-innovative-medicines
United-european-gastroenterology-week
Cincinnati-college
Johnson-innovative
Severely-active-crohn
Participants-with-moderately
Achieved-clinical-remission
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Di...
New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose grou.
United-states
Japan
Calgary
Alberta
Canada
California
San-diego
Spring-house
British-columbia
Horsham
Saskatchewan
Americans
vimarsana © 2020. All Rights Reserved.